April 6, 2016
Dow AgroSciences and TeselaGen Advance Biodesign Technologies for Agriculture
INDIANAPOLIS & SAN FRANCISCO–(BUSINESS WIRE)–Using the power of nature in conjunction with advanced technology and informatics to produce and develop solutions for farmers is essential to advance agriculture. Today, TeselaGen Biotechnology Inc., and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), announced they have entered into a collaboration to produce a state-of-the-art biological design automation platform that can speed discovery work.
“TeselaGen has created a powerful suite of tools for DNA design,” said Daniel R. Kittle, Ph.D., Vice President, Research and Development, Dow AgroSciences. “These tools have the potential to accelerate our discovery efforts focused on providing sustainable solutions to help feed the growing world.”
With a secure computational environment to design and create molecular biology research information, the private-cloud platform will enable scientists at Dow AgroSciences to advance their research to find new crop protection and seed products at an accelerated pace.
Dr. Michael Fero, Chief Executive Officer, TeselaGen, said, “TeselaGen is a platform that automates and optimizes protocol generation for biomanufacturing. This collaboration is a great complement to our previous work in medical and industrial biotechnology. We are very excited to now bring our platform to bear on problems facing farmers.”
About Dow AgroSciences
Dow AgroSciences discovers, develops, and brings to market crop protection and plant biotechnology solutions for the growing world. Based in Indianapolis, Indiana, USA, Dow AgroSciences is a wholly owned subsidiary of The Dow Chemical Company and had annual global sales of $6.4 billion in 2015. Learn more at www.dowagro.com. Follow Dow AgroSciences onFacebook, Twitter, LinkedIn, and Google+, or subscribe to our News Release RSS Feed.
TeselaGen builds secure enterprise quality software platforms for designing, building and precision editing DNA, enabling the development of vaccines, biologic medicines, and sustainably sourced chemicals. TeselaGen is privately held and is based in the software hub of San Francisco, CA. The company has received early recognition in the form of four US National Science Foundation funding awards, a US Department of Energy funding award and a Bio-IT World Best Practices Award. TeselaGen uses its proprietary Synthetic Evolution® technology for efficient rapid prototyping and editing of recombinant molecules. Follow TeselaGen on Facebook, Twitter, LinkedIn, and Google+, and learn more at teselagen.com.